{"filing":{"accession_number":"0001193125-26-333912","cik":"0001835579","ticker":"IMA","company_name":"ImageneBio, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"d166048d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1835579/000119312526333912/d166048d8k.htm"},"events":[{"id":24491,"run_id":22193,"accession_number":"0001193125-26-333912","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"ImageneBio disclosed its financial results for the quarter ended June 30, 2026 via press release attached as Exhibit 99.1, including condensed consolidated balance sheets and statements of operations. This is a standard quarterly earnings release filed under Item 2.02, with specific financial metrics (R\u0026D expenses of $6.7M, G\u0026A expenses of $5.1M, net loss of $10.2M) and cash position ($136.2M) that would materially inform investor assessment of the company's financial condition and runway.","company_name":"ImageneBio, Inc.","ticker":"IMA","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25058,"accession_number":"0001193125-26-333912","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ImageneBio disclosed its financial results for the quarter ended June 30, 2026 via press release attached as Exhibit 99.1, including condensed consolidated balance sheets and statements of operations. This is a standard quarterly earnings release filed under Item 2.02, with specific financial metrics (R\u0026D expenses of $6.7M, G\u0026A expenses of $5.1M, net loss of $10.2M) and cash position ($136.2M) that would materially inform investor assessment of the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:40:23.205379+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25058,"accession_number":"0001193125-26-333912","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"ImageneBio disclosed its financial results for the quarter ended June 30, 2026 via press release attached as Exhibit 99.1, including condensed consolidated balance sheets and statements of operations. This is a standard quarterly earnings release filed under Item 2.02, with specific financial metrics (R\u0026D expenses of $6.7M, G\u0026A expenses of $5.1M, net loss of $10.2M) and cash position ($136.2M) that would materially inform investor assessment of the company's financial condition and runway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:40:23.205379+00:00","company_name":"ImageneBio, Inc.","ticker":"IMA","filing_date":"2026-08-05"}]}